Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma - a cross-sectional questionnaire study.

Fiche publication

Date publication

juillet 2025

Journal

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Reitmajer M, Schäffeler N, Bach A, Nanz L, Amaral T, Leiter U, Flatz L, Forschner A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40277327

Résumé

Immune checkpoint inhibitors and targeted therapies have improved survival in patients with stage IV melanoma. However, the challenges faced by long-term survivors remain unclear. The long-term toxicity and psychosocial impact of these treatments in real-world patients have yet to be reported.